BR0113006A - Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso - Google Patents

Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso

Info

Publication number
BR0113006A
BR0113006A BR0113006-4A BR0113006A BR0113006A BR 0113006 A BR0113006 A BR 0113006A BR 0113006 A BR0113006 A BR 0113006A BR 0113006 A BR0113006 A BR 0113006A
Authority
BR
Brazil
Prior art keywords
storage disease
glycogen storage
individual
treating type
treating
Prior art date
Application number
BR0113006-4A
Other languages
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0113006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Publication of BR0113006A publication Critical patent/BR0113006A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MéTODO PARA TRATAR DOENçA DE ARMAZENAMENTO DE GLICOGêNIO TIPO II NUM INDIVìDUO E SEU USO". São descritos métodos para tratar doença de armazenamento de glicogênio tipo II administrando-se <244>-glicosidase ácida, bem como composições para uso no tratamento de doença de armazenamento de glicogênio tipo II.
BR0113006-4A 2000-07-18 2001-07-10 Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso BR0113006A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
BR0113006A true BR0113006A (pt) 2004-10-19

Family

ID=22818451

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113006-4A BR0113006A (pt) 2000-07-18 2001-07-10 Método para tratar doença de armazenamento de glicogênio tipo ii num indivìduo e seu uso

Country Status (17)

Country Link
US (10) US7056712B2 (pt)
EP (4) EP1301201B1 (pt)
JP (10) JP5113312B2 (pt)
AT (1) ATE355075T1 (pt)
AU (3) AU2001271941B2 (pt)
BR (1) BR0113006A (pt)
CA (1) CA2416492C (pt)
CY (2) CY1120977T1 (pt)
DE (1) DE60126947T2 (pt)
DK (5) DK1782825T3 (pt)
ES (5) ES2277931T3 (pt)
LT (3) LT3449934T (pt)
MX (1) MXPA03000474A (pt)
PT (5) PT3449934T (pt)
SI (3) SI3449934T1 (pt)
TW (1) TWI280882B (pt)
WO (1) WO2002005841A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1782825T3 (da) * 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
US20060018882A1 (en) * 2004-06-21 2006-01-26 Kaemmerer William F Medical devices and methods for delivering compositions to cells
JP5433133B2 (ja) * 2003-01-22 2014-03-05 デューク・ユニヴァーシティ リソソームポリペプチドを発現するための改善された構築物
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
ES2629853T3 (es) * 2008-05-07 2017-08-16 Biomarin Pharmaceutical Inc. Péptidos de dirección lisosómica y usos de los mismos
US9050333B2 (en) 2008-07-08 2015-06-09 Duke University Method of treating glycogen storage disease type III with human acid α-glucosidase
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
KR20160010526A (ko) 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
EP3292871B1 (en) * 2015-05-07 2021-06-23 The University of Tokyo Nanoreactor using polyion complex polymersomes, and method for producing same
CA2996906A1 (en) * 2015-08-31 2017-03-09 Duke University Methods and compositions for the treatment of cytoplasmic glycogen storage disorders
US10940125B2 (en) 2015-09-18 2021-03-09 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102747683B1 (ko) 2015-12-30 2024-12-31 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
JP7046003B2 (ja) 2016-03-30 2022-04-01 アミカス セラピューティックス インコーポレイテッド 高ｍ６ｐ組換えタンパク質の選択方法
SG11201808455VA (en) 2016-03-30 2018-10-30 Amicus Therapeutics Inc Formulations comprising recombinant acid alpha-glucosidase
AU2017250298B2 (en) 2016-04-15 2024-10-03 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
ES2950808T3 (es) 2017-05-15 2023-10-13 Amicus Therapeutics Inc Alfa-glucosidasa ácida humana recombinante
JP7449223B2 (ja) 2017-09-22 2024-03-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ムコ多糖症ｉｉ型を治療するための遺伝子療法
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof
IT202300005733A1 (it) * 2023-03-27 2024-09-27 St Microelectronics Int Nv Circuito di comunicazione, sistema e procedimento corrispondenti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
WO1999058691A2 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CA2353522A1 (en) 1998-12-07 2000-06-15 Pharming Intellectual Property B.V. Treatment of pompe's disease
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
DK1782825T3 (da) 2000-07-18 2014-11-03 Univ Duke Behandling af glycogenlagringssygdom type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
US20050123531A1 (en) 2005-06-09
ES2799882T3 (es) 2020-12-22
US20020110551A1 (en) 2002-08-15
US9370556B2 (en) 2016-06-21
JP6163216B2 (ja) 2017-07-12
EP2767291B1 (en) 2016-09-14
JP5113312B2 (ja) 2013-01-09
JP2018002749A (ja) 2018-01-11
JP2013231081A (ja) 2013-11-14
AU2010200487A1 (en) 2010-03-04
DK3108895T3 (en) 2018-11-26
US10792341B2 (en) 2020-10-06
ES2599401T3 (es) 2017-02-01
TWI280882B (en) 2007-05-11
JP2014185187A (ja) 2014-10-02
LT3108895T (lt) 2018-11-26
DE60126947D1 (de) 2007-04-12
LT2767291T (lt) 2016-11-25
PT3449934T (pt) 2020-06-25
JP2020019822A (ja) 2020-02-06
JP2016056206A (ja) 2016-04-21
EP2767291A2 (en) 2014-08-20
AU2001271941B2 (en) 2007-03-01
JP2017137357A (ja) 2017-08-10
HK1197656A1 (en) 2015-02-06
HK1054690A1 (en) 2003-12-12
AU7194101A (en) 2002-01-30
CA2416492A1 (en) 2002-01-24
JP2004503598A (ja) 2004-02-05
ES2523024T3 (es) 2014-11-20
CA2416492C (en) 2008-04-29
US7056712B2 (en) 2006-06-06
DE60126947T2 (de) 2007-10-31
US20160184410A1 (en) 2016-06-30
EP3108895A1 (en) 2016-12-28
US20120058132A1 (en) 2012-03-08
US8900552B2 (en) 2014-12-02
DK1782825T3 (da) 2014-11-03
ATE355075T1 (de) 2006-03-15
EP1301201B1 (en) 2007-02-28
EP3449934A1 (en) 2019-03-06
US20080175833A1 (en) 2008-07-24
EP2767291A3 (en) 2014-10-08
DK3449934T3 (da) 2020-06-29
CY1120977T1 (el) 2019-12-11
JP2018199721A (ja) 2018-12-20
ES2277931T3 (es) 2007-08-01
HK1103363A1 (en) 2007-12-21
MXPA03000474A (es) 2003-10-06
DK1301201T3 (da) 2007-04-02
PT2767291T (pt) 2016-10-25
US20150004152A1 (en) 2015-01-01
WO2002005841A1 (en) 2002-01-24
US20130195834A1 (en) 2013-08-01
US20100254966A1 (en) 2010-10-07
EP3449934B1 (en) 2020-05-20
SI2767291T1 (sl) 2016-11-30
ES2700865T3 (es) 2019-02-19
US20180185457A1 (en) 2018-07-05
CY1123084T1 (el) 2021-10-29
JP5792774B2 (ja) 2015-10-14
SI3449934T1 (sl) 2020-09-30
JP2012006953A (ja) 2012-01-12
PT1301201E (pt) 2007-03-30
US9907839B2 (en) 2018-03-06
EP1301201A1 (en) 2003-04-16
PT1782825E (pt) 2014-11-04
EP3108895B1 (en) 2018-09-19
DK2767291T3 (en) 2016-12-05
JP2008081507A (ja) 2008-04-10
US20210169996A1 (en) 2021-06-10
SI3108895T1 (sl) 2019-01-31
LT3449934T (lt) 2020-08-10
PT3108895T (pt) 2018-12-18

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
DE602004012745D1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
CY1105221T1 (el) Ιατρικη χρηση θυρεοειδομιμητικων ενωσεων για την θepαπευτικη αγωγη της τριχοπτωσης και φαρμακευτικες συνθεσεις
BR0207585A (pt) Método para melhorar o desempenho de crescimento de um animal, composição promotora do crescimento, e, construção para a liberação in vivo de uma quantidade eficaz de citocina
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
TR200201250T2 (tr) Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri.
BRPI0418157A (pt) terapêutica de tumores alogênicos
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
EA200601249A1 (ru) Пиперазины, пригодные для лечения боли
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ES2146226T3 (es) Utilizacion de una composicion celular para el tratamiento de los organismos humanos o animales.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60336504D1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
ATE296631T1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation
ES2044534T3 (es) Un metodo para la preparacion de una composicion tromboliticamente activa.
BRPI0411567A (pt) uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente
EP1782825A3 (en) Treatment of glycogen storage diseases type II
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
BR0111291A (pt) Composições aquosas condroprotetoras que apresentam limitações de ph definidas para emissão eficaz
SE0004026D0 (sv) New use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.